These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 39088242)
1. Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19. Casadevall A; McConnell S; Focosi D Expert Opin Biol Ther; 2024 Aug; 24(8):787-797. PubMed ID: 39088242 [TBL] [Abstract][Full Text] [Related]
2. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody. Phan T; Zitzmann C; Chew KW; Smith DM; Daar ES; Wohl DA; Eron JJ; Currier JS; Hughes MD; Choudhary MC; Deo R; Li JZ; Ribeiro RM; Ke R; Perelson AS; PLoS Pathog; 2024 Apr; 20(4):e1011680. PubMed ID: 38635853 [TBL] [Abstract][Full Text] [Related]
3. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X MAbs; 2021; 13(1):1953683. PubMed ID: 34313527 [TBL] [Abstract][Full Text] [Related]
4. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
5. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis. Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134 [TBL] [Abstract][Full Text] [Related]
6. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923 [TBL] [Abstract][Full Text] [Related]
7. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284 [TBL] [Abstract][Full Text] [Related]
8. Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies. Müller K; Girl P; Giebl A; Gruetzner S; Antwerpen M; Khatamzas E; Wölfel R; von Buttlar H Virus Genes; 2021 Dec; 57(6):502-509. PubMed ID: 34608598 [TBL] [Abstract][Full Text] [Related]
9. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Chen RE; Winkler ES; Case JB; Aziati ID; Bricker TL; Joshi A; Darling TL; Ying B; Errico JM; Shrihari S; VanBlargan LA; Xie X; Gilchuk P; Zost SJ; Droit L; Liu Z; Stumpf S; Wang D; Handley SA; Stine WB; Shi PY; Davis-Gardner ME; Suthar MS; Knight MG; Andino R; Chiu CY; Ellebedy AH; Fremont DH; Whelan SPJ; Crowe JE; Purcell L; Corti D; Boon ACM; Diamond MS Nature; 2021 Aug; 596(7870):103-108. PubMed ID: 34153975 [TBL] [Abstract][Full Text] [Related]
11. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902 [TBL] [Abstract][Full Text] [Related]
12. Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. Errico JM; Zhao H; Chen RE; Liu Z; Case JB; Ma M; Schmitz AJ; Rau MJ; Fitzpatrick JAJ; Shi PY; Diamond MS; Whelan SPJ; Ellebedy AH; Fremont DH Cell Rep; 2021 Oct; 37(4):109881. PubMed ID: 34655519 [TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern. Casadevall A; Focosi D J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36919696 [TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012 [TBL] [Abstract][Full Text] [Related]
15. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
16. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823 [TBL] [Abstract][Full Text] [Related]